Publication | Closed Access

Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study

Hematological MalignancyRichter Transformation SubgroupMedicineMalignant Blood DisorderPharmacologyPathologyBtk InhibitorImmune Checkpoint InhibitorAnti-cancer AgentBruin StudyOncologyRadiation OncologyCancer ResearchDrug Discovery